Monte Rosa Therapeutics Appoints New CMO, Directors
Ticker: GLUE · Form: 8-K · Filed: May 30, 2024 · CIK: 1826457
| Field | Detail |
|---|---|
| Company | Monte Rosa Therapeutics, Inc. (GLUE) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-appointment
TL;DR
Monte Rosa names new CMO, adds two directors to the board.
AI Summary
Monte Rosa Therapeutics, Inc. announced on May 28, 2024, the appointment of Dr. Jonathan G. Hall as Chief Medical Officer and the election of Dr. Hall and Ms. Sarah E. Kelly to its Board of Directors. The company also disclosed compensatory arrangements for these individuals. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
The appointment of a new Chief Medical Officer and board members can signal a strategic shift or expansion in the company's clinical development and governance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of personnel changes and board appointments, with no immediate financial or operational risks indicated.
Key Players & Entities
- Monte Rosa Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan G. Hall (person) — Appointed Chief Medical Officer and Elected Director
- Ms. Sarah E. Kelly (person) — Elected Director
- May 28, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan G. Hall has been appointed as the new Chief Medical Officer.
Who were elected to the Board of Directors?
Dr. Jonathan G. Hall and Ms. Sarah E. Kelly were elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is May 28, 2024.
What is the principal executive office address of Monte Rosa Therapeutics?
The principal executive office address is 321 Harrison Avenue, Suite 900, Boston, MA 02118.
What is the SIC code for Monte Rosa Therapeutics?
The Standard Industrial Classification (SIC) code is 2836 for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 778 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2024-05-30 07:18:01
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share GLUE The Nasdaq
Filing Documents
- d836893d8k.htm (8-K) — 26KB
- d836893dex991.htm (EX-99.1) — 7KB
- g836893dsp5.jpg (GRAPHIC) — 8KB
- 0001193125-24-149802.txt ( ) — 171KB
- glue-20240528.xsd (EX-101.SCH) — 3KB
- glue-20240528_lab.xml (EX-101.LAB) — 18KB
- glue-20240528_pre.xml (EX-101.PRE) — 11KB
- d836893d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits 99.1 Press Release issued by Monte Rosa Therapeutics, Inc. dated May 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monte Rosa Therapeutics, Inc. Date: May 30, 2024 By: /s/ Markus Warmuth Markus Warmuth President and Chief Executive Officer